BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27721149)

  • 1. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
    Singh A; Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum.
    Dickerman BK; Elsworth B; Cobbold SA; Nie CQ; McConville MJ; Crabb BS; Gilson PR
    Sci Rep; 2016 Nov; 6():37502. PubMed ID: 27874068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances on patents of
    Gehlot P; Vyas VK
    Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
    Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
    J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
    Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
    J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.
    Mandt REK; Luth MR; Tye MA; Mazitschek R; Ottilie S; Winzeler EA; Lafuente-Monasterio MJ; Gamo FJ; Wirth DF; Lukens AK
    Elife; 2023 Sep; 12():. PubMed ID: 37737220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
    Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
    Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
    Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
    J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.
    Ross LS; Lafuente-Monasterio MJ; Sakata-Kato T; Mandt REK; Gamo FJ; Wirth DF; Lukens AK
    ACS Infect Dis; 2018 Apr; 4(4):508-515. PubMed ID: 29336544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
    Boschi D; Pippione AC; Sainas S; Lolli ML
    Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 3,4-Dihydro-2
    Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase.
    Ittarat I; Asawamahasakda W; Meshnick SR
    Exp Parasitol; 1994 Aug; 79(1):50-6. PubMed ID: 8050525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
    Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
    Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
    Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
    J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model.
    Booker ML; Bastos CM; Kramer ML; Barker RH; Skerlj R; Sidhu AB; Deng X; Celatka C; Cortese JF; Guerrero Bravo JE; Crespo Llado KN; Serrano AE; Angulo-Barturen I; Jiménez-Díaz MB; Viera S; Garuti H; Wittlin S; Papastogiannidis P; Lin JW; Janse CJ; Khan SM; Duraisingh M; Coleman B; Goldsmith EJ; Phillips MA; Munoz B; Wirth DF; Klinger JD; Wiegand R; Sybertz E
    J Biol Chem; 2010 Oct; 285(43):33054-33064. PubMed ID: 20702404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
    Heikkilä T; Ramsey C; Davies M; Galtier C; Stead AM; Johnson AP; Fishwick CW; Boa AN; McConkey GA
    J Med Chem; 2007 Jan; 50(2):186-91. PubMed ID: 17228860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
    Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
    J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.